Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: An in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1216-1220

  Kot, Marta ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Caffeine metabolism; cDNA expressed CYP1A2; Cytochrome P450; DDC; Furafylline; Human liver microsomes; Ticlopidine

Indexed keywords

CAFFEINE; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; TICLOPIDINE;

ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; PROTEIN EXPRESSION;

EID: 76049090459     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70187-2     Document Type: Article

References (18)

1. Bourrie M, Meunier V, Berger Y, Fabre G: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther, 1996, 277, 321-331.
2. Chang TK, Gonzalez FJ, Waxman DJ: Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys, 1994, 311, 437-442.
3. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci, 2001, 21, 143-148.
4. Donovan JL, De Vane CL: A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull, 2001, 35, 30-48.
5. Eagling VA, Tjia JF, Back DJ: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol, 1998, 45, 107-114.
6. Fisone G, Borgvist A, Usiello A: Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci, 2004, 61, 857-872.
7. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D: Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450. Biochemistry, 2001, 12112-12122.
8. Kot M, Daniel WA: Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep, 2008, 60, 789-797.
9. Kot M, Daniel WA: Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: The pathway and concentration dependence. Biochem Pharmacol, 2008, 75, 1538-1549.
10. Kot M, Daniel WA: The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol, 2008, 76, 543-551.
11. Margolis JM, Obach RS: Impact of nonspecific binding to microsomes and phospholipids on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug metabolism. Drug Metab Dispos, 2003, 31, 606-611.
12. Masimirembwa C, Otter C, Berg M, Jönsson M, Leidvik B, Jonsson E, Johansson T et al.: Heterologous expression and kinetic characterization of human cytochromes P-450: Validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos, 1999, 27, 1117-1122.
13. Newton DJ, Wang RW, Lu AYH: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos, 1995, 23, 154-158.
14. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsu M: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 1996, 26, 681-693.
15. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M: Assessment od specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica, 2000, 30, 327-343.
16. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O: Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos, 2004, 32, 626-631.
17. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA: Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci, 2006, 26, 535-541.
18. Xu K, Xu YH, Chen JF, Schwarzschild MA: Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett, 2002, 322,13-16.